Real-world Treatment Patterns, Survival, and Economic Burden among Elderly MCL Patients Previously Treated with cBTKis
Squires P, Puckett J, Ryland K, Kamal-Bahl S, Raut M, Doshi J, Huntington S. Real-world Treatment Patterns, Survival, and Economic Burden among Elderly MCL Patients Previously Treated with cBTKis. Clinical Lymphoma Myeloma & Leukemia 2024 DOI: 10.1016/j.clml.2024.05.023.Peer-Reviewed Original ResearchR/R MCLOverall survivalTreatment patternsRelapsed/refractory mantle cell lymphomaReal-world treatment patternsBruton tyrosine kinase inhibitorCovalent Bruton tyrosine kinase inhibitorMantle cell lymphomaTyrosine kinase inhibitorsDevelopment of novel therapeuticsMCL patientsCell lymphomaThird-lineRetrospective studyTreatment initiationResponse durationAdverse eventsElderly patientsKinase inhibitorsPatient subpopulationsPatientsAll-causeNovel therapeuticsEconomic burdenSurvivalReal-world patterns and sequences of targeted therapy use in chronic lymphocytic leukemia and small lymphocytic lymphoma in the United States: a longitudinal study
Huntington S, Cheng W, Sarpong E, Leng S, Farooqui M, Agu U, Catillon M, Lejeune D, Downes N, Matay L, Duh M, De Nigris E. Real-world patterns and sequences of targeted therapy use in chronic lymphocytic leukemia and small lymphocytic lymphoma in the United States: a longitudinal study. Leukemia & Lymphoma 2024, 65: 932-942. PMID: 38696747, DOI: 10.1080/10428194.2024.2331631.Peer-Reviewed Original ResearchSequential targeted therapyLymphocytic lymphomaTherapy useB-cell lymphoma 2 inhibitorChronic lymphocytic leukemia/small lymphocytic lymphomaBruton tyrosine kinase inhibitorTargeted therapy useSmall lymphocytic lymphomaChronic lymphocytic leukemiaTyrosine kinase inhibitorsProportion of patientsClaims-based studyFirst-lineLymphocytic leukemiaTargeted therapyClinical outcomesB cellsKinase inhibitorsTreatment sequenceReal-world patternsTherapyCLL/SLLBTKiCD20Lymphoma